MMP28 gene expression is regulated by Sp1 transcription factor acetylation. 2010

Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
University of East Anglia, Norwich, UK.

MMP-28 (epilysin) is a recently cloned member of the MMP (matrix metalloproteinase) family. It is highly expressed in the skin by keratinocytes, the developing and regenerating nervous system and a number of other normal human tissues, as well as a number of carcinomas. The MMP28 promoter has previously been cloned and characterized identifying a conserved GT-box that binds Sp1/Sp3 (specificity proteins 1 and 3) proteins and is essential for the basal expression of the gene. The present study demonstrates that MMP28 expression is induced by HDAC (histone deacetylase) inhibitors and that this effect is mediated through the GT-box. Transient transfection assays have shown that the induction of MMP28 expression by the HDAC inhibitior TSA (trichostatin A) is mediated via Sp1 at the GT-box. Immunoprecipitation experiments have shown that the acetylation of Sp1 and Sp3 is increased by TSA treatment; however, no effect on DNA binding was observed. Histone acetyltransferases such as p300 and P/CAF [p300/CREB (cAMP-response-element-binding protein)-binding protein-associated factor] increased induction of the MMP28 promoter by Sp1. Knockdown of HDAC1 using siRNA (small interfering RNA) also induces the MMP28 promoter. Oligonucleotide pulldown identified STRAP (serine/threonine kinase receptor-associated protein) as a further protein recruited to the MMP28 promoter and acting functionally with Sp1.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001881 Borates Inorganic or organic salts and esters of boric acid. Borate
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
February 2007, Gene,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
December 2001, Nucleic acids research,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
March 2005, Biochemical and biophysical research communications,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
September 2016, Molecular medicine reports,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
March 2001, The Journal of biological chemistry,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
August 2000, Cellular and molecular life sciences : CMLS,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
June 2020, BMC molecular and cell biology,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
January 2007, Nephron. Experimental nephrology,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
March 1999, The Journal of biological chemistry,
Tracey E Swingler, and Lara Kevorkian, and Kirsty L Culley, and Sara A Illman, and David A Young, and Andrew E Parker, and Jouko Lohi, and Ian M Clark
September 1992, Molecular and cellular biology,
Copied contents to your clipboard!